Back to rankings

The Clorox Company (CLX)

NEUTRAL
Consumer DefensiveHousehold & Personal ProductsUnited States

Fundamental

47

Price

$106.19

Market Cap

$12.98B

Part 1 · What the company is worth

Overview

Clorox makes household staples sold under well-known names: bleach and cleaning sprays under its own Clorox brand, trash bags under Glad, charcoal under Kingsford, and personal-care and health products including Burt's Bees. It manufactures most of what it sells, ships it to large retailers, and relies on repeat, habitual purchases rather than one-off sales — a household restocks bleach or trash bags on a predictable cycle regardless of the wider economy.

How it makes money

Revenue comes from selling packaged goods to a concentrated set of large retailers, who then resell to shoppers. Margins depend on the cost of raw materials such as resin and chemicals, on manufacturing efficiency, and on holding shelf space and brand loyalty against cheaper private-label alternatives that retailers sell alongside Clorox's own products. The company reports results across four segments split by product category and by U.S. versus international markets.

Revenue by segment

Health and Wellness38.1%

Cleaning and disinfecting products under Clorox, plus water filtration under Brita and vitamins under Natural Vitality.

Household28.3%

Trash bags under Glad, cat litter under Fresh Step and Scoop Away, and charcoal under Kingsford.

Lifestyle18.4%

Food products including Hidden Valley dressings, and personal care through Burt's Bees.

International15.1%

The same core product categories sold outside the United States, mainly in Latin America and Canada.

Competitive moat

Brand · Narrow

Names like Clorox, Glad and Kingsford have been the default choice on U.S. shelves for generations, which lets the company hold shelf space and charge more than an unbranded equivalent. The advantage is narrow: retailer store brands compete directly in nearly every category, and a large retailer with real pricing leverage can push back hard on Clorox's terms.

What drives demand

Defensive

Cleaning products, trash bags and personal care items are routine, non-discretionary household purchases that people keep buying in a downturn, which makes volume relatively stable across the economic cycle. The bigger swings in results tend to come from input-cost inflation and from consumers trading down to private label when money is tight, not from skipping the purchase altogether.

Key risks

  • Retailer concentration — With Walmart alone worth nearly 27% of net sales, large retailers have the leverage to demand better pricing terms or to favour their own private-label products over Clorox's brands.
  • Input cost and supply chain disruption — Volatile commodity, packaging, labour, energy and logistics costs, along with the risk of supply disruption from conflicts such as those in Ukraine, the Middle East, or tensions between China and Taiwan, can raise costs faster than prices can be adjusted.
  • Cybersecurity — The company depends heavily on information technology systems and has already suffered a major cyberattack, in August 2023, that disrupted operations; a repeat incident could again halt production and shipments.
  • Private-label competition — Store-brand alternatives, often priced well below Clorox's products, compete in nearly every category the company sells in, forcing continued spending on marketing and innovation to defend market share.

Customer concentration

Top customers account for 27% of revenue

Walmart and its affiliates accounted for nearly 27% of net sales in fiscal 2025, giving a single retailer significant leverage over shelf placement, promotional terms and pricing.

The case for

Buyers argue that Clorox's brands are habit-forming staples that hold shelf space no private label can fully dislodge, and that the company's cost-savings programme and full recovery from the 2023 cyberattack position it to grow margins even on roughly flat sales.

The case against

Sellers worry that with Walmart alone worth over a quarter of sales, Clorox has limited room to push back on retailer demands, and that persistent private-label competition plus input-cost inflation could keep squeezing volumes and margins at the same time.

Written by the editors, published on August 18, 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$6.76B

Trailing 12 months (through 3/31/2026)

Net Income

$756M

Trailing 12 months (through 3/31/2026)

Free Cash Flow

$761M

Total Equity

$321M

Total Liabilities

$5.08B

Current Ratio

0.84

Interest Coverage

-

Debt/EBITDA

3.94

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

Fairly Valued

Fair Value

$110.05

Current Price

$106.19

Margin of Safety

+3.5%

Fair Value Range

$71.53 - $148.56

Estimation Methods

Analyst Target:$101.65
DCF:$193.39
PE-based:$77.90
Graham Growth:$35.98
EPV:$64.12
Analyst Consensus:Hold (1B / 17H / 9S)
Last Earnings Surprise:-0.49%

Valuation Metrics

P/E Ratio

17.40

ROE

252.3%

P/B Ratio

40.43

P/FCF

34.10

Gross Margin

43.8%

ROIC

-

Profitability Radar

Value Creation (Economic Moat)

ROIC

-

WACC

6.3%

ROIC − WACC

-

Fundamental Analysis Criteria

Passed (11)

  • EPS shows upward trend
  • Gross Margin 43.8%
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 181.1%
  • Earnings Quality (OCF/NI) 0.76
  • Share Dilution -0.2%
  • Net Margin Trend 11.2% vs 9.9%
  • Piotroski F-Score 8/9

Failed (12)

  • EPS CAGR 4.22%
  • Price CAGR -1.17%
  • P/FCF 34.10
  • P/B Ratio 40.43
  • Debt/Equity ratio
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • Revenue Growth 5Y -1.8%
  • Analyst Consensus 4% Buy
  • Earnings Surprise avg 1.8%

Unavailable (5)

  • ROIC NaN%
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

8/9

Strong financial health

score
criteria

Earnings Quality

0.76

Moderate: some gap between profits and cash

Share Dilution

-0.2%

Buying back shares. Shareholder friendly

Governance

Executive Team

NameTitleAge
Ms. Linda J. RendleCEO & Chairman47
Mr. Luc BelletExecutive VP & CFO46
Ms. Nina BartonExecutive VP and Chief Growth & Strategy Officer51
Ms. Laura E. PeckVP, Chief Accounting Officer & Corporate Controller48
Ms. Kirsten M. MarrinerExecutive VP & Chief Administrative Officer52
Ms. Lisah BurhanVice President of Investor Relations-

Audit Risk

7

Board Risk

3

Compensation Risk

6

Shareholder Rights Risk

8

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for CLX, sourced from Markets Gazette.

  • 22d agoPOSITIVE
    Clorox Expects Full-Year Sales Boost From Purell Deal

    The Clorox Company announced fiscal fourth-quarter earnings that surpassed analyst forecasts, signaling resilience despite challenges. While sales volumes were down and the recent acquisition of GOJO Industries, the maker of Purell, incurred additional logistics costs, the overall financial performance indicates effective management. The company anticipates a full-year sales boost stemming from the Purell integration, suggesting a positive outlook for future revenue streams. Investors will be watching the successful integration of GOJO and its impact on Clorox's market position and profitability in the coming quarters.

via Markets Gazette